WuXi AppTec

Global Aging And Advanced Therapies Will Expand Outsourcing

AnalystHighTarget

Not Invested

Consensus Narrative from 18 Analysts

Published

03 Aug 25

Updated

27 Aug 25

AnalystHighTarget's Fair Value

CN¥138.00

30.7% undervalued

27 Aug

CN¥95.69

147.2%

4.4%

147.2%

4.4%

Author's Valuation

CN¥138.0

30.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CN¥138.0

30.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.24%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.32%

Calculation

CN¥21.64b

Earnings '28

33.13x

PE Ratio '28

CN¥717.05b

Market Cap '28

CN¥717.05b

Market Cap '28

4.20b

No. shares '28

CN¥170.58

Share Price '28

CN¥170.58 Share Price '28

Discounted to 2025 @ 7.32% p.a.

CN¥138.00

Fair Value '25